E-Mail
M102 is a disease-modifying drug candidate for motor neuron disease (MND) that was discovered by Sheffield scientists in 2013
University of Sheffield partnership with Aclipse Therapeutics awarded a £1.6m grant by the Medical Research Council (MRC) to advance the translational development of M102
MRC grant follows funding from FightMND to take M102 into clinical trials with patients
MND - also known as Amyotrophic Lateral Sclerosis (ALS) - is a devastating disease that affects 5,000 people in the UK and 450,000 people worldwide
Researchers from the University of Sheffield's Institute for Translational Neuroscience (SITraN) have been awarded a £1.6 million grant from the Medical Research Council (MRC). The grant will support their partnership with Aclipse Therapeutics to advance the translational development of M102 - a drug candidate for the treatment of motor neuron disease (MND).